{"schema_version":"secwatch.filing_event.v1","accession":"0001650664-25-000106","form_type":"8-K","ticker":"EDIT","cik":"0001650664","company_name":"Editas Medicine, Inc.","filed_at":"2025-06-12T23:59:59+00:00","discovered_at":"2026-05-14T18:02:49.201305+00:00","generated_at":"2026-05-19T10:43:19.683518+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Editas reports 58% HBG1/2 editing in NHPs after single tLNP dose at 5 months","bullets":["Mean on-target editing of 58% in HSCs at 5 months post single IV dose of proprietary tLNP, exceeding ≥25% therapeutic threshold.","Data presented at EHA 2025; supports in vivo approach for sickle cell disease and beta thalassemia.","Biodistribution shows significant liver de-targeting vs. standard LNPs in NHPs.","Uses AsCas12a to edit HBG1/2 promoters, mimicking hereditary persistence of fetal hemoglobin."],"urls":{"canonical":"https://secwatch.observer/filing/0001650664-25-000106","json":"https://secwatch.observer/filing/0001650664-25-000106.json","markdown":"https://secwatch.observer/filing/0001650664-25-000106.md","text":"https://secwatch.observer/filing/0001650664-25-000106.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1650664/000165066425000106/0001650664-25-000106-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1650664/000165066425000106/edit-20250612.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-19T10:43:19.683518+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}